Poseida Therapeutics‘ P-BCMA-101 eradicates tumors in mouse models of multiple myeloma and creates memory T-cells that go on the attack when the disease returns, preclinical…
The patient-led Global Myeloma Action Network (GMAN) recently designated March 30 as International Myeloma Action Day to raise awareness of multiple myeloma, advocate for early detection and…
The Leukemia & Lymphoma Society (LLS) and the National Black Church Initiative (NBCI) are closing March, Myeloma Awareness Month, with the start of…
The first-ever Multiple Myeloma Research Foundation (MMRF) Patient Summit was held March 25 in Denver to help patients and caregivers learn more about…
Antibody-drug conjugates (ADCs), a class of drugs in which a cancer-targeting therapy is attached to a specific monoclonal antibody without harming healthy cells, continue to…
BioLineRx’s investigational drug BL-8040 has demonstrated positive interim results from a Phase 2 trial as a monotherapy for the mobilization and collection of donor blood stem…
By activating the immune system, the experimental drug LCL161 has the potential to fight myeloma in both mice and humans, according to a new study by…
The cancer charity Myeloma UK has launched a Phase 1 clinical trial testing Reolysin (pelareorep), a modulator of the immune system and cytotoxic agent, in myeloma…
Don Wright, who recently finished his 100th marathon while on active treatment for multiple myeloma, will continue running, but now with the support of the…
Multiple myeloma patients undergoing autologous stem cell transplants (ASCT) may strongly benefit from SELLAS‘ WT-1 cancer vaccine, galinpepimut-S, according to recent data from a…